Radiopharm Theranostics Ltd (RADX) Operating Income (2023 - 2026)

Radiopharm Theranostics (RADX) has reported Operating Income for 4 consecutive years, with -$711294.1 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Income rose 98.14% year-over-year to -$711294.1 in Q2 2026; TTM through Jun 2026 was -$120.6 million, a N/A change from a year earlier, with the FY2026 full-year figure at -$385651.8, up 98.99% from the prior year.
• Operating Income was -$711294.1 for Q2 2026 at Radiopharm Theranostics, up from -$38.2 million in the prior quarter.
• Over five years, Operating Income peaked at -$711294.1 in Q2 2026 and troughed at -$47.2 million in Q2 2024.
• A 4-year average of -$30.1 million and a median of -$36.3 million in 2023 frame the typical range for Operating Income.
• Across the five-year window, Operating Income plunged 36.89% in 2024 and surged 98.14% in 2026, its largest moves.
• Over 4 years, Operating Income stood at -$34.5 million in 2023, then slumped by 36.89% to -$47.2 million in 2024, then climbed by 19.14% to -$38.2 million in 2025, then jumped by 98.14% to -$711294.1 in 2026.
• The last three Operating Income figures came in at -$711294.1 (Q2 2026), -$38.2 million (Q2 2025), and -$47.2 million (Q2 2024), per Business Quant data.